261 related articles for article (PubMed ID: 11719454)
1. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.
Parajuli P; Pisarev V; Sublet J; Steffel A; Varney M; Singh R; LaFace D; Talmadge JE
Cancer Res; 2001 Nov; 61(22):8227-34. PubMed ID: 11719454
[TBL] [Abstract][Full Text] [Related]
2. Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.
Sang H; Pisarev VM; Chavez J; Robinson S; Guo Y; Hatcher L; Munger C; Talmadge CB; Solheim JC; Singh RK; Talmadge JE
Cancer Gene Ther; 2005 Apr; 12(4):427-37. PubMed ID: 15678151
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
5. Modulating dendritic cells to optimize mucosal immunization protocols.
Williamson E; Westrich GM; Viney JL
J Immunol; 1999 Oct; 163(7):3668-75. PubMed ID: 10490961
[TBL] [Abstract][Full Text] [Related]
6. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
[TBL] [Abstract][Full Text] [Related]
7. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
8. [Immunization with dendritic cells infected with mTERT adenovirus vector effectively elicits immunity against mouse H22 hepatoma in vivo].
Jiang N; Wang GS; Li H; Zhang J; Zhang JF; Yi SH; Yi HM; Yang Y; Cai CJ; Lu MQ; Chen GH
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):405-9. PubMed ID: 19950546
[TBL] [Abstract][Full Text] [Related]
9. Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection.
Solheim JC; Reber AJ; Ashour AE; Robinson S; Futakuchi M; Kurz SG; Hood K; Fields RR; Shafer LR; Cornell D; Sutjipto S; Zurawski S; LaFace DM; Singh RK; Talmadge JE
Cancer Gene Ther; 2007 Apr; 14(4):364-71. PubMed ID: 17235356
[TBL] [Abstract][Full Text] [Related]
10. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
11. IL-1beta, but not IL-1alpha, is required for antigen-specific T cell activation and the induction of local inflammation in the delayed-type hypersensitivity responses.
Nambu A; Nakae S; Iwakura Y
Int Immunol; 2006 May; 18(5):701-12. PubMed ID: 16569679
[TBL] [Abstract][Full Text] [Related]
12. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
[TBL] [Abstract][Full Text] [Related]
13. Differential capacity of CD8+ alpha or CD8- alpha dendritic cell subsets to prime for eosinophilic airway inflammation in the T-helper type 2-prone milieu of the lung.
Hammad H; de Vries VC; Maldonado-Lopez R; Moser M; Maliszewski C; Hoogsteden HC; Lambrecht BN
Clin Exp Allergy; 2004 Dec; 34(12):1834-40. PubMed ID: 15663556
[TBL] [Abstract][Full Text] [Related]
14. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
15. Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice.
Xu J; Xu W; Chen X; Zhao D; Wang Y
Vaccine; 2008 Aug; 26(35):4519-25. PubMed ID: 18598729
[TBL] [Abstract][Full Text] [Related]
16. [Anti-tumor immune response of dendritic cells transfected with wild-type p53 gene].
Liu HJ; Xin JB; Li ZY; Xiong XZ; Tao XN; Hu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Dec; 31(12):902-7. PubMed ID: 19134406
[TBL] [Abstract][Full Text] [Related]
17. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice.
Nakajima C; Uekusa Y; Iwasaki M; Yamaguchi N; Mukai T; Gao P; Tomura M; Ono S; Tsujimura T; Fujiwara H; Hamaoka T
Cancer Res; 2001 Apr; 61(8):3399-405. PubMed ID: 11309299
[TBL] [Abstract][Full Text] [Related]
18. Ethanol consumption modifies dendritic cell antigen presentation in mice.
Heinz R; Waltenbaugh C
Alcohol Clin Exp Res; 2007 Oct; 31(10):1759-71. PubMed ID: 17850646
[TBL] [Abstract][Full Text] [Related]
19. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
Yang AS; Lattime EC
Cancer Res; 2003 May; 63(9):2150-7. PubMed ID: 12727833
[TBL] [Abstract][Full Text] [Related]
20. IFN-gamma-producing ability as a possible marker for the protective T cells against Mycobacterium bovis BCG in mice.
Kawamura I; Tsukada H; Yoshikawa H; Fujita M; Nomoto K; Mitsuyama M
J Immunol; 1992 May; 148(9):2887-93. PubMed ID: 1374103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
